Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
In Guru Portfolios
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
| Cathie Wood | ARK Investment Management LLC | 0.3% | +0.17% |
| Steven Cohen | Point72 Asset Management, L.P. | 0.0% | +0.04% |
| Kenneth Griffin | CITADEL ADVISORS LLC | 0.0% | +0.00% |
About
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers.
Target Price
The average target price of CMPS is 23.4 and suggests 104% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre